Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.90 Million

Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report $26.90 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $17.10 million and the highest estimate coming in at $42.38 million. Alnylam Pharmaceuticals posted sales of $17.45 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 54.2%. The business is scheduled to announce its next earnings report before the market opens on Thursday, February 8th.

On average, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $26.90 million for the current year, with estimates ranging from $56.59 million to $94.36 million. For the next fiscal year, analysts anticipate that the company will post sales of $102.44 million per share, with estimates ranging from $13.74 million to $159.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Alnylam Pharmaceuticals.

Several equities analysts recently issued reports on the company. Barclays boosted their price target on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, November 8th. FBR & Co started coverage on Alnylam Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $150.00 price objective on the stock. Cowen reiterated an “outperform” rating and issued a $151.00 price objective (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Chardan Capital reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $123.93.

Alnylam Pharmaceuticals (ALNY) opened at $124.50 on Friday. Alnylam Pharmaceuticals has a 12 month low of $39.66 and a 12 month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The stock has a market capitalization of $12,726.96, a PE ratio of -23.71 and a beta of 2.69.

In other news, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the transaction, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total value of $9,387,640.00. Following the completion of the transaction, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last three months. 4.30% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Prudential Financial Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 200 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 23.8% in the 2nd quarter. Principal Financial Group Inc. now owns 15,256 shares of the biopharmaceutical company’s stock worth $1,217,000 after acquiring an additional 2,928 shares in the last quarter. Teachers Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 5.5% in the 2nd quarter. Teachers Advisors LLC now owns 84,679 shares of the biopharmaceutical company’s stock worth $6,754,000 after acquiring an additional 4,441 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 6.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,270 shares of the biopharmaceutical company’s stock worth $739,000 after acquiring an additional 585 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $575,000. 88.44% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.90 Million” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/04/zacks-analysts-anticipate-alnylam-pharmaceuticals-inc-alny-will-post-quarterly-sales-of-26-90-million.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply